Thoughts on whether n30 approach to cf will compete with vertex or could be added to improve cf modulators. And if I could impose on you thirdmeinvestor to explain how the n30 drugs work and compare to vertex and your thoughts on using both to improve. Also now that vertex is working with other pharma on hep, what about about vertex and company which has ataluren...could that be in works?
Verity, I had been following their work, but I could not get much from the published work. Their molecules can correct trafficking to inflammation, and are effective in treating animal models of asthma, chronic obstructive pulmonary disease, and inflammatory bowel disease. They may claim to cure cancer too.
Only quantitative result on CFTR function was found in a recent poster presented in their website. The effectiveness of N91115 on the in vitro conductance is not much different from the control (buffer solution) and it is nowhere near that of the normal CFTR(~3 vs. ~25).